Carousel Slider

Small trial of Bemdaneprocel, which aims to replace dopamine-producing neurons, raises hope for treatment The loss of dopamine-producing neurons with Parkinson’s causes symptoms including a tremor, slow movements and muscle stiffness. Photograph: David Davies/PA Scientists have reported early success in a trial of an experimental cell therapy for Parkinson’s disease, raising hope for patients. Bemdaneprocel therapy is at an early stage, and the year-long trial involved just 12 patients, but the positive outcome is viewed as significant after decades of setbacks in the hunt for an effective treatment. Developed by BlueRock therapeutics, a subsidiary of the pharmaceutical company Bayer, it…

UCI MIND faculty member and professor of pathology, Elizabeth Head, PhD, is quoted in last week's Alzforum article about Alzheimer's disease immunotherapies and the high rates of cerebrovascular pathology in people with Down syndrome.   To read the story, visit Alzforum from August 25th. Dr. Elizabeth Head

Downtown Los Angeles seen in the hazy distance. Photo: Caroline Brehman/Zuma Press Smoggy air can hurt your health even after the smoke has cleared. But you can lower your risk. Some animal research suggests that fine particles can make their way into the brain, says Masashi Kitazawa, an associate professor of environmental and occupational health at the University of California, Irvine. He recently co-wrote a study that found that older mice who were exposed to polluted air were at an increased risk of developing Alzheimer’s disease than those who got purified air. Even the younger mice who were exposed to polluted…

More Asian Americans, Native Hawaiians and Pacific Islanders sought for studies on aging UCI’s Joshua Grill is one of three principal investigators for the National Institute on Aging grant that will fund CARE 2.0. Steve Zylius / UCI August 2, 2023—With a $16 million grant from the National Institute on Aging, the University of California, San Francisco and the University of California, Irvine will work with community partners to improve the representation of Asian American, Native Hawaiian and Pacific Islander adults in research on aging, caregiving, and Alzheimer’s disease and related dementias. The new project builds on a previous effort…

Quest Diagnostics recently announced the launch of a direct-to-consumer blood test to detect amyloid plaques in the brain. The test examines the ratio of Ab42/Ab40 in the plasma. Based on the Quest website, the test results are provided in numeric fashion, as well as based on categories of low, intermediate, and high risk of amyloid presence in the brain (with lower numbers on the plasma Ab ratio associated with higher likelihood of amyloid being present in the brain). As can be seen on the website, there is a high degree of overlap on test results among those with elevated compared…

Barrington and Vickie Riley pose at the Emory University Brain Health Center in Atlanta, Georgia, U.S., July 12, 2023. The Riley's, who have been married more than 35 years, participated in the Charlie and Harriet Shaffer Cognitive Empowerment Program. Barrington Riley has mild cognitive impairment. REUTERS/Alyssa Pointer Dr. Joshua Grill, a University of California, Irvine, Alzheimer's researcher, who collaborated with Eisai and other researchers to analyze two trials for Leqembi and two for an earlier anti-amyloid drug, also found that Black, Hispanic and Asian people were more likely to be screened out of clinical trials because the amount of amyloid…

From cutting-edge research on Alzheimer’s disease to an innovative effort to include environmental justice and community engagement in climate and sustainability science research and education, University of California, Irvine scholars, scientists and physicians are blazing new paths to help change the world. And their impact keeps growing. In fiscal 2022-23, which ended June 30, UCI received the most research funding in campus history: $653 million in grants and contracts. Awards from federal and state agencies, leading foundations and forward-thinking companies rose by 12.7 percent over the 2021-22 total of $580 million, reflecting strong support for UCI’s top-ranked faculty, first-rate facilities,…

UCI MIND researchers, Christian Salazar, PhD, MPH, and Maria Corona, PhD, have been awarded a UCI ICTS 2023 Campus-Community Researcher Incubator Award for their project, "Improving Knowledge and Awareness of Alzheimer's Disease and Related Dementias among Promotores in Santa Ana, California.”  The team will partner with the OC based, Latino Health Access to train and support community health workers, called promotores, to increase awareness of dementia in Hispanic and Latinx communities.

Results were presented on Monday from the first-of-its kind Anti-Amyloid treatment in Asymptomatic Alzheimer’s (A4) Study. The A4 was a more than 10-year project to conduct one of the first and largest “preclinical” Alzheimer’s disease clinical trials, testing a compound for potential disease-slowing properties before memory problems begin in a population deemed at risk based on an amyloid PET scan biomarker test. Unfortunately, the drug studied, solanezumab, did not slow memory worsening compared to placebo in this trial. This was surprising given the previous findings in which solanezumab had appeared to have very small but seemingly real effects in symptomatic…

Results were presented on Monday for TRAILBLAZER-ALZ-2, a registration trial of the monoclonal antibody donanemab, which was previously announced as positive. The data were highly convincing that donanemab has a significant effect of slowing disease progression in Alzheimer’s disease and almost certainly points to a full clinical approval for the drug by the FDA in the future. The primary analytic group under study in this TRAILBLAZER study (there are several different clinical trials of donanemab sponsored by Eil Lilly under the moniker of “TRAILBLAZER”) was patients with “low-to-medium tau burden,” assessed with a tau PET scan. Unlike the previous trial…

Can reading and similar activities help stave off dementia? Image credit: Simone Wave/Stocksy? MNT spoke with Dr. Karen D. Lincoln, a professor in the Department of Environmental and Occupational Health at the University of California, Irvine. She noted that while some evidence suggests that cognitive exercises like crossword puzzles or word games slow cognitive decline in those with mild cognitive impairment, the evidence is inconclusive. … “f you like to play dominoes, spades, or bid whist, you are actually engaging in healthy brain exercises,” she said. “Not necessarily because the games are very challenging and require good memory, but because the…

July 6, 2023—Today, the US Food and Drug Administration granted full approval to the drug lecanemab (brand name Leqembi®), a monoclonal antibody that has been demonstrated to lower levels of amyloid plaques in the brain and slow cognitive and functional decline in people living with Mild Cognitive Impairment and mild dementia due to Alzheimer’s disease. The approval is the first full approval of a new drug for Alzheimer’s disease in nearly 2 decades. The full, or traditional, approval is distinguished from “accelerated” approval, which lecanemab was also granted in January of this year. The full approval communicates that the agency…

On June 9, The US Food and Drug Administration convened members of the updated Peripheral and Central Nervous System Drugs Advisory Committee to review the available data for lecanemab, the monoclonal antibody treatment for early Alzheimer’s disease developed by Eisai and Biogen. The members voted unanimously, 6-0, in favor of approval. Lecanemab was recently granted accelerated approval by FDA, based on demonstration that treatment with the infused medication could lower brain amyloid levels. Based on results from a large Phase 3 trial in which lecanemab demonstrated efficacy in slowing disease progression over 18-months, the agency will now consider full approval for…

UCI MIND Director, Dr. Joshua Grill, named one of this year’s OC50 (50 people shaping the future of healthcare in Orange County) in the Orange County Business Journal.  Read the article here.

Masashi Kitazawa, Associate Professor of Environmental and Occupational Health, and his team found exposure to traffic-related air pollution led to memory loss and cognitive decline and triggered neurological pathways associated with the onset of Alzheimer’s disease. "Public and environmental regulatory agencies need to accelerate efforts to reduce particulate matter levels in order to reduce the risk of Alzheimer's disease and other serious health conditions," says Michael Kleinman. (Credit: Getty Images) Read the article here.

David Sultzer, MD May 12, 2023–Brexpiprazole has now been approved by the FDA for the treatment of agitation in Alzheimer’s dementia.  Agitated behaviors are common in those with moderate or advanced Alzheimer’s dementia and these symptoms contribute substantially to caregiver burden, institutionalization, and faster cognitive decline.  Yesterday’s decision marks the first approval in the United States of a medication for these symptoms. The approval was based on the results of three 12-week treatment studies.  The studies collectively showed modest reduction in the frequency of specific agitated behaviors and lower severity on a clinician-rated measure.  In one of the studies, 56%…

May 3, 2023–Eli Lilly and company announced today (https://investor.lilly.com/news-releases/news-release-details/lillys-donanemab-significantly-slowed-cognitive-and-functional) the positive topline results from their Phase 3 clinical trial of donanemab, a monoclonal antibody that rapidly lowers beta amyloid levels in the brain of people with Alzheimer’s disease. The release indicated that patients treated with donanemab experienced significantly slower cognitive and functional decline, compared to those receiving placebo, over 18 months. The primary outcome was a composite measure known as the integrated Alzheimer's Disease Rating Scale (iADRS, a tool that borrows pieces of other instruments to look at elements key in early disease) and was reported as demonstrating a 35%…

New number crunching from the Alzheimer's Orange County estimates that the number of folks enduring this sort of heartbreak has essentially doubled since 2014 in the O.C. That’s a startling jump, from 84,000 to 164,000 people, which works out to about 5% of our total population. … “The new number is believable, especially if a difference from the previous estimate is the inclusion of mild cognitive impairment as a category,” said Dr. Joshua D. Grill, Professor of Neurobiology & Behavior and noted Alzheimer’s researcher at UC Irvine . Joshua Grill, PhD “Orange County is ‘grayer’ than the rest of the country,…

Dr. Frank LaFerla, Dean of the School of Biological Sciences and UCI MIND faculty member speaks at local educational event for the Alzheimer's Foundation of America. Frank LaFerla, PhD Read about the event and the prevalence of Alzheimer's disease in California here.

OC World produced documentary "Hope Dies Last", featuring UCI MIND faculty members, Drs. Joshua Grill and Leslie Thompson, wins the Golden Mike Award for best documentary. "Hope Dies Last" creates a narrative around the impact of Alzheimer's disease on California communities and the stories of families who find hope in the darkest of times. The documentary, produced by OC World, was awarded Best Long Form Programming or Documentary at the 73rd Annual Golden Mike Awards. Read the full article here.    View the documentary here. https://youtu.be/wABhpdiZO0E

The UC Irvine Institute for Memory Impairments and Neurological Disorders (UCI MIND) is pleased to announce that the inaugural recipient of the “UCI MIND Joan and Don Beall Scholar Award” is S. Ahmad Sajjadi, MD, PhD. Dr. Sajjadi is an Associate Professor of Neurology in the UCI School of Medicine. A clinician scientist with an established track record of studying different neurodegenerative pathologies across the aging spectrum, Dr. Sajjadi has demonstrated himself as an outstanding investigator and an important contributor to Alzheimer’s disease and related dementias (ADRD) research and clinical care at UCI. He is an investigator in the UCI Alzheimer’s…

Dr. Joshua Grill and colleagues at the University of Pittsburgh have been awarded a 3.5 million dollar grant by the National Institute on Aging to advance the field’s understanding of real-world patient and family member reactions to biomarker-informed Alzheimer’s disease and related disorders (ADRD) diagnoses and to provide critical information for directing post-diagnostic resources to monitor and support those most in need. Read the full news story about this important research here Joshua D. Grill, PhDDirector, UCI MIND; Professor, Psychiatry and Human Behavior and Neurobiology and Behaviorphoto: Steve Zylius/UCI  

UCI MIND faculty member and psychiatrist, David Sultzer, MD, has been awarded a $12 million dollar grant by the NIA to test a novel prevention treatment. He, along with two other Southern California researchers will test an experimental vaccine to prevent Alzheimer's disease.  The Orange County Register covered the story. Read the article here.

Dr. Mathew Blurton-Jones UCI MIND faculty member and Professor of Neurobiology and Behavior, Mathew Blurton-Jones Jones, PhD, has been awarded Early Career Innovator/Emerging Innovation of the Year by UCI Beall Applied Innovation. Read the full article here.

In July 2022, students from Santa Ana and Anaheim high schools learn about neuroanatomy as part of the UCI MIND Beall Scholar Program to Inspire Future STEM Leaders. Support from Joan and Don Beall will allow for the program to continue. UCI MIND Irvine, Calif., Jan. 31, 2023 — Sustained support from philanthropists Joan and Don Beall to the the Institute for Memory Impairments and Neurological Disorders will allow for the continuation of an educational outreach program in Orange County high schools and the creation of a new research award for an early career researcher. “We are grateful for the…

UCI School of Medicine highlighted innovative research performed in the lab of Xiangmin Xu, PhD, UCI MIND faculty member and professor and Chancellor’s Fellow of anatomy and neurobiology in the UCI School of Medicine.  Dr. Xu and colleagues have found that sporadic Alzheimer's disease can be modeled in a non-murine rodent called the Chilean degu. "Our findings, taken together, show spontaneous AD-like correlative phenotypes in cognitive performance and neuropathology in aged, outbred degus. This supports that aged degus are a useful and practical model of natural sporadic AD." Xiangmin Xu Read the article in the February edition of the UCI School…

The recent FDA approval of lecanemab has generated a lot of buzz in recent days and UCI MIND director, Joshua Grill, PhD has been asked to comment in various highly visible media outlets including the Washington Post and today, in National Geographic. 

Only Mutants. While wild-type human microglia perished in mice after two months of CSF1R inhibitor treatment (left), G795A microglia expanded to fill the entire brain (green, right). UCI MIND faculty member and professor, Mathew Blurton-Jones, PhD, is featured in AlzForum for his lab's recent collaborative work on creating a new strain of resistant microglia. Lead author and graduate student in the Blurton-Jones lab, Jean Paul Chadarevian, along with collaborators at the University of Pennsylvania published their innovative work in Journal of Experimental Medicine in the December 2022 issue. Read the full article here >

The actor Chris Hemsworth recently publicly disclosed that he learned that he carries two copies of the Alzheimer’s disease risk gene Apolipoprotein  (APOE) e4 (https://www.goodmorningamerica.com/culture/story/chris-hemsworth-discovers-risk-alzheimers-disease-series-limitless-93442609). We’ve previously discussed direct-to-consumer genetic testing that includes the option for APOE testing on the UCI MIND blog (https://mind.uci.edu/fda-approves-23andme-limited-direct-consumer-genetic-risk-testing/). APOE is the strongest known genetic risk factor for Alzheimer’s disease. People who carry one or two copies of the e4 allele are at increased risk for Alzheimer’s disease, while people who carry the e2 allele are at lower risk (most people carry two copies of the e3 allele). But people with e4 don’t always develop…